In the present issue of Critical Care, Dr Heininger and colleagues present a new study in which they assessed the clinical outcomes of nonimmunosuppressed critically ill patients with severe sepsis who had reactivation of cytomegalovirus (CMV) [1] . Th ey found that intensive care unit (ICU) stay, hospital stay and mechanical ventilation were all signifi cantly prolonged in patients with CMV reactivation compared with those without reactivation, but the mortality rate was not diff erent between groups. How can this be explained?
Abstract
Cytomegalovirus (CMV) is a ubiquitous virus present in approximately two-thirds of the healthy population. This virus rarely causes an active disease in healthy individuals, but it is among the most common opportunistic infections in immunocompromised patients such as solid organ transplant recipients, patients receiving chemotherapy for cancer or patients with human immunodefi ciency virus. Critically ill patients who are immunocompetent before intensive care unit admission may also become more prone to develop active CMV infection if they have prolonged hospitalizations, high disease severity, and severe sepsis. The development of active CMV infection in these critically ill patients has been associated with a signifi cantly higher risk of death in several previous studies. The present issue of Critical Care brings a new study by Heininger and colleagues in which the authors found that patients with severe sepsis who developed active CMV infection had signifi cantly longer intensive care unit and hospital stays, prolonged mechanical ventilation, but no changes in mortality compared to patients without CMV infection. We discuss the possible reasons for their fi ndings (for example, selection bias and low (20%) statistical power to detect mortality endpoints), and also perform an update of our previous meta-analysis with the addition of Heininger and colleagues' study to verify whether the higher mortality rate with CMV holds. Our updated meta-analysis with approximately 1,000 patients shows that active CMV infection continues to be associated with a signifi cant 81% higher mortality rate than that in critically ill patients without active CMV infection.
could lead to signifi cant false-positive results due to more active CMV infection and higher mortality in the control arm; or to false-negative results due to more active CMV infection and higher mortality in the treatment arm.
Th is new study by Heininger and colleagues showed a signifi cant association between active CMV infection and major morbidity fi ndings such as prolonged ICU/hospital stay and mechanical ventilation, but no increased mortality [1] . Even though this was a well-performed observa tional study, however, the lack of randomization probably led to selection bias; for example, patients without active CMV infection compared with patients with active CMV infection had more septic shock and peritonitis, less urinary tract infections, and higher Simplifi ed Acute Physiology Score II/Sequential Organ Failure Assessment scores -all of which are known to be associated with higher mortality. Hence, this small nonrandomized study could easily have been confounded by these important baseline imbalances, which could be the reason for false-negative results; that is, the more severely ill patients (due to baseline imbalances) without active CMV infection did not allow the study to detect the expected higher mortality in patients with active CMV infection.
Also, based on Heininger and colleagues' small sample size, the statistical power to detect diff erences in mortality between groups was extremely low (20%), which could have further increased the probability of falsenegative results. If we assume that this high likelihood of false-negative results is true, then the addition of this new study to our previous meta-analysis should not change our previous results of higher mortality with active CMV infection. If we assume that their results are not false-negative, then the addition of this negative study should change the results of our meta-analysis. In order to clarify this assumption, we performed an update of the mortality analysis from our previous study. To be com plete, we also added the study by Chiche and colleagues that was published after our meta-analysis [9] . Two more studies were thus added to our initial metaanalysis and the results are shown in Figure 1 . Our updated results consistently show that active CMV infection continues to be associated with a signifi cant 81% higher mortality rate than that in patients without active CMV infection. Th is fi nding strongly suggests the results from Heininger and colleagues were false-negative with respect to mortality outcomes. In fact, their worse morbidity outcomes in patients with active CMV infection fi t perfectly with both previous studies and our recent meta-analysis, as well as with the higher mortality seen in patients with active CMV infection.
Based on all current evidence, it is unquestionable that active CMV infection is associated with higher morbidity and higher mortality in critically ill patients who were not previously immunosuppressed. Nonetheless, the million-dollar question still remains to be answered: is CMV causing mortality or is CMV accompanying mortality (that is, refl ecting higher severity of illness)? Only a large prospective, randomized, non-interventional cohort study with adequate statistical power and comprehensive study design as previously recommended [8] , can bring light to resolve such an important issue for our critically ill patients. 
